Cargando…

BCL-2 Inhibitor Venetoclax Induces Autophagy-Associated Cell Death, Cell Cycle Arrest, and Apoptosis in Human Breast Cancer Cells

INTRODUCTION: Venetoclax (VCX) is a selective BCL-2 inhibitor approved for the treatment of leukemia and lymphoma. However, the mechanisms of anti-cancer effect of VCX either as a monotherapy or in combination with other chemotherapeutic agents against breast cancer need investigation. METHODS: Brea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alhoshani, Ali, Alatawi, Fahad O, Al-Anazi, Fawaz E, Attafi, Ibraheem M, Zeidan, Asad, Agouni, Abdelali, El Gamal, Heba M, Shamoon, Licia S, Khalaf, Sarah, Korashy, Hesham M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7783200/ https://www.ncbi.nlm.nih.gov/pubmed/33414642 http://dx.doi.org/10.2147/OTT.S281519

Ejemplares similares

Interplay between Endoplasmic Reticulum Stress and Large Extracellular Vesicles (Microparticles) in Endothelial Cell Dysfunction
por: Osman, Aisha, et al.
Publicado: (2020)

Endoplasmic Reticulum (ER) Stress-Generated Extracellular Vesicles (Microparticles) Self-Perpetuate ER Stress and Mediate Endothelial Cell Dysfunction Independently of Cell Survival
por: Osman, Aisha, et al.
Publicado: (2020)

The Role of Protein Tyrosine Phosphatase (PTP)-1B in Cardiovascular Disease and Its Interplay with Insulin Resistance
por: Abdelsalam, Shahenda S., et al.
Publicado: (2019)

Endoplasmic Reticulum Stress: A Critical Molecular Driver of Endothelial Dysfunction and Cardiovascular Disturbances Associated with Diabetes
por: Maamoun, Hatem, et al.
Publicado: (2019)

Insight into the physiological and pathological roles of the aryl hydrocarbon receptor pathway in glucose homeostasis, insulin resistance, and diabetes development
por: Sayed, Tahseen S., et al.
Publicado: (2022)

Influence of the Aryl Hydrocarbon Receptor Activating Environmental Pollutants on Autism Spectrum Disorder
por: Dhulkifle, Hevna, et al.
Publicado: (2021)

Molecular Mechanisms of Adiponectin-Induced Attenuation of Mechanical Stretch-Mediated Vascular Remodeling
por: Ghantous, Crystal M., et al.
Publicado: (2020)

Sestrin2 as a Protective Shield against Cardiovascular Disease
por: Zahid, Muhammad Ammar, et al.
Publicado: (2023)

Between Inflammation and Autophagy: The Role of Leptin-Adiponectin Axis in Cardiac Remodeling
por: Kamareddine, Layla, et al.
Publicado: (2021)

Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation
por: Al-Dhfyan, Abdullah, et al.
Publicado: (2017)

Erratum to: Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation
por: Al-Dhfyan, Abdullah, et al.
Publicado: (2017)

Correction to: Lead nitrate induces inflammation and apoptosis in rat lungs through the activation of NF‑κB and AhR signaling pathways
por: Attafi, Ibraheem M., et al.
Publicado: (2022)

Lead Nitrate Induces Inflammation and Apoptosis in Rat Lungs Through the Activation of NF-κB and AhR Signaling Pathways
por: Attafi, Ibraheem M., et al.
Publicado: (2022)

Gold-containing compound BDG-I inhibits the growth of A549 lung cancer cells through the deregulation of miRNA expression
por: Alhoshani, Ali, et al.
Publicado: (2018)

DLBCL Cells with Acquired Resistance to Venetoclax Are Not Sensitized to BIRD-2 But Can Be Resensitized to Venetoclax through Bcl-XL Inhibition
por: Kerkhofs, Martijn, et al.
Publicado: (2020)

Metformin attenuates V-domain Ig suppressor of T-cell activation through the aryl hydrocarbon receptor pathway in Melanoma: In Vivo and In Vitro Studies
por: Alanazi, Fawaz E., et al.
Publicado: (2022)

In vivo and in vitro studies evaluating the chemopreventive effect of metformin on the aryl hydrocarbon receptor-mediated breast carcinogenesis
por: Alhoshani, Ali, et al.
Publicado: (2021)

Sorafenib, rapamycin, and venetoclax attenuate doxorubicin-induced senescence and promote apoptosis in HCT116 cells
por: As Sobeai, Homood M., et al.
Publicado: (2022)

Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition
por: Roca-Portoles, Alba, et al.
Publicado: (2020)

Hematologic Tumor Cell Resistance to the BCL-2 Inhibitor Venetoclax: A Product of Its Microenvironment?
por: Leverson, Joel D., et al.
Publicado: (2018)

Metformin Induces Different Responses in Clear Cell Renal Cell Carcinoma Caki Cell Lines
por: Pasha, Mazhar, et al.
Publicado: (2019)

Microparticles as Potential Mediators of High Glucose-Induced Renal Cell Injury
por: Ravindran, Sreenithya, et al.
Publicado: (2019)

Crosstalk between aryl hydrocarbon receptor (AhR) and BCL-2 pathways suggests the use of AhR antagonist to maintain normal differentiation state of mammary epithelial cells during BCL-2 inhibition therapy
por: Al-Dhfyan, Abdullah, et al.
Publicado: (2022)

ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
por: Cang, Shundong, et al.
Publicado: (2015)

Reciprocal sensitivity of diffuse large B-cell lymphoma cells to Bcl-2 inhibitors BIRD-2 versus venetoclax
por: Vervloessem, Tamara, et al.
Publicado: (2017)

High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition
por: Bate-Eya, Laurel T., et al.
Publicado: (2016)

Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations
por: Birkinshaw, Richard W., et al.
Publicado: (2019)

Combinatorial BCL2 Family Expression in Acute Myeloid Leukemia Stem Cells Predicts Clinical Response to Azacitidine/Venetoclax
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Dexamethasone treatment promotes Bcl-2-dependence in multiple myeloma resulting in sensitivity to Venetoclax
por: Matulis, Shannon M., et al.
Publicado: (2015)

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax
por: Avsec, Damjan, et al.
Publicado: (2022)

Combination strategies to overcome resistance to the BCL2 inhibitor venetoclax in hematologic malignancies
por: Yue, XiaoYan, et al.
Publicado: (2020)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

PB1893: CLONAL EVOLUTION WITH BCL-2 AMPLIFICATION DURING VENETOCLAX TREATMENT
por: Rodríguez-Afonso, Jorge, et al.
Publicado: (2023)

Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies
por: Thomalla, D., et al.
Publicado: (2022)

Venetoclax Induces Cardiotoxicity through Modulation of Oxidative-Stress-Mediated Cardiac Inflammation and Apoptosis via NF-κB and BCL-2 Pathway
por: AlAsmari, Abdullah F., et al.
Publicado: (2022)

Targeting BCL2 with venetoclax is a promising therapeutic strategy for “double-proteinexpression” lymphoma with MYC and BCL2 rearrangements
por: Uchida, Akiko, et al.
Publicado: (2019)

CS2164 and Venetoclax Show Synergistic Antitumoral Activities in High Grade B-Cell Lymphomas With MYC and BCL2 Rearrangements
por: Yuan, Delin, et al.
Publicado: (2021)

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature review
por: Cao, Qiang, et al.
Publicado: (2023)

Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies
por: Chong, Stephen Jun Fei, et al.
Publicado: (2023)

Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
por: Kaufman, Jonathan L., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6uca2qtfv653r3l5mqmqsdfp0q